

REMARKS

Claims 1-11, 14 and 15 are pending in the application. Claim 11 is withdrawn from examination. Claim 15 has been added. Support for the newly added claim lies in the claims as originally filed and the working examples. No new matter is believed added.

The claims have been made the subject of a restriction requirement under 35 USC §121 and §372:

- Group I: claim(s) 1-10 and 14, drawn to a chemical compound, a pharmaceutical Composition, and a process for preparing a chemical compound of formula (I)
- Group II: claim(s) 11, drawn to a method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase using the chemical compound of formula I.

Applicants elect the compounds of Group I without traverse.

The Examiner further requests an election of a single disclosed species for prosecution on the merits. Applicants elect the compound of Example 1, 6-(5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl)-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide-1-oxide.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



/
Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090